Spyre Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Feb 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 19, 2026
SYRE$103.86+7.5%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 7.
SPYRE THERAPEUTICS, INC.
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Page | |
|---|---|
| Audited Consolidated Financial Statements | |
| Report of Independent Registered Public Accounting Firm (ID 185 KPMG LLP) | 110 |
| Report of Independent Registered Public Accounting Firm (ID 238 Pricewaterhouse Coopers LLC) | 112 |
| Consolidated Balance Sheets | 113 |
| Consolidated Statements of Operations | 114 |
| Consolidated Statements of Comprehensive Loss | 115 |
| Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders’ Equity | 116 |
| Consolidated Statements of Cash Flows | 118 |
| Notes to Consolidated Financial Statements | 120 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.